| Nov 19, 2009 | 08:00 | TOMI(ES) Licenses Its Infectious Disease Control Technology to Degmor Industries for New York City |
| TOMI Environmental Solutions, Inc., (OTCBB:TOMZ) www.tomiesinc.com, the Professional Infectious Disease and Air Remediation Company, which has safely harnessed two of the most powerful disinfectants known to man: ozone and hydroxyl radicals, announced today that TOMI(ES) and Degmor Industries, a leading environmental remediation company in the New York area have signed a license agreement to buy TOMI(ES) equipment and have its technicians certified and trained in the application of TOMI(ES) technology for the control of infectious disease and air remediation. TOMI(ES) equipment prevents the spread of airborne and surface contaminates, along with treating and protecting indoor spaces that have been infected by all types of pathogens.
continued... |
|
| Nov 19, 2009 | 07:00 | EcoBlu Signs Exclusive Licensing Agreement With Hartindo Fire Protection Supplier Megola |
| EcoBlu Products, Inc. (OTCBB:ECOB), provider of eco-friendly, protected wood products, has signed an exclusive licensing agreement with fire protection supplier Megola, (Pink Sheets:MGOA), adding to the company's proprietary BLUWOOD(TM) technology which protects wood from the harmful effects of mold, rot-decay and termites. The exclusive partnership enables EcoBlu to protect both dimensional lumber and engineered wood against another devastating threat continued... |
|
| Nov 16, 2009 | 06:00 | GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction |
| GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) today announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX(R)), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.
continued... |
|
| Nov 5, 2009 | 09:00 | TapImmune Signs License Agreement With Crucell N.V. |
 | TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V.
continued... |
|
| Nov 4, 2009 | 09:45 | EcoBlu Products Signs Exclusive Sales and Marketing Agreement |
| EcoBlu Products, Inc., (OTCBB:ECOB) announced today it has entered into an exclusive licensing agreement with Luxor Industrial Corporation of Vancouver, British Columbia, Canada for their patented IBS2000(R) Engineered Bridging. The agreement is for an exclusive worldwide sales and marketing license, excluding Canada.
continued... |
|
| Oct 29, 2009 | 07:00 | Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody |
 | Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, and sanofi-aventis (NYSE Euronext:SAN) (NYSE:SNY) announced today a global collaboration and license agreement to develop a BiTE(R) antibody against an antigen present at the surface of carcinoma cells. BiTE antibodies are novel therapeutic antibodies that activate a patient's T cells to seek out and destroy cancer cells.
continued... |
|
| Oct 29, 2009 | 07:00 | ACI Worldwide Announces Alliance With Bell ID to Provide Smart Card Solutions |
 | ACI Worldwide, Inc. (Nasdaq:ACIW), a leading international provider of electronic payments software and solutions, today announced that it has entered into an exclusive agreement with Bell ID for ACI to license Bell ID's solutions for smart card management to financial markets and retailers around the world. As part of this agreement, ACI will market and license the ANDiS suite of products, which will continue to be developed by Bell ID from its Dutch headquarters.
continued... |
|
| Oct 28, 2009 | 06:30 | FuelCell Energy and POSCO Power Sign License Agreement to Localize Products for South Korean Market |
 | FuelCell Energy, Inc. (Nasdaq:FCEL), a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government, and utility customers, today announced the signing of a Licensing Agreement allowing POSCO Power to manufacture fuel cell stack modules from cell and module components provided by FuelCell Energy. These fuel cell modules will be combined with balance-of-plant manufactured in South Korea to complete electricity-producing fuel cell power plants for sale in South Korea. The License Agreement includes an upfront license fee of $10 million which was paid at signing as well as an ongoing royalty, initially set at 4.1% of the revenues generated by sales of the fuel cell stack modules by POSCO Power. Additionally, POSCO Power closed on its previously announced purchase of $25 million in FuelCell Energy common stock at a purchase price of $3.59 per share, the price agreed to on June 9, 2009.
continued... |
|
| Oct 21, 2009 | 08:00 | NEC BIGLOBE and LogMeIn Sign Distribution Agreement for LogMeIn Products in Japan |
 | LogMeIn, Inc. (Nasdaq:LOGM), a leading provider of remote connectivity solutions, today announced that it has signed a distribution agreement with NEC BIGLOBE, a leading Japanese internet service provider (ISP) and broadband media provider. Under the terms of the agreement, NEC BIGLOBE becomes an official distributor of LogMeIn's continued... |
|
| Oct 15, 2009 | 08:47 | Cryo-Cell Announces C'elle(SM) Technology License Agreement With Cryopraxis Cryobiology Ltd. |
| Cryo-Cell International, Inc. (OTCBB:CCEL) ("Company"), one of the largest and most established leaders in stem cell innovation, today announced that it has signed an exclusive technology license agreement with Cryopraxis Cryobiology Ltd. ("Cryopraxis"), a privately-held global regenerative technology leader located in Rio De Janeiro, Brazil. The license agreement will allow Cryopraxis to market and manufacture proprietary C'elle(SM) menstrual stem cell technology including the processing and storage of menstrual stem cells (MenSCs) throughout Brazil. The exclusive technology license agreement with Cryopraxis is expected to provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells in Brazil.
continued... |
|
| Oct 15, 2009 | 08:30 | Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals |
| Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), and Eleison Pharmaceuticals, Inc., today announced the execution of a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide. Glufosfamide is a novel small molecule that has been evaluated by Threshold in a Phase 3 clinical trial and multiple Phase 2 clinical trials.
continued... |
|
| Oct 6, 2009 | 09:00 | MIPS Technologies Licenses MIPS32(R) Architecture to Altera Corporation |
| MIPS Technologies, Inc. (Nasdaq:MIPS), a leading provider of industry-standard processor architectures and cores for digital consumer, home networking, wireless, communications and business applications, today announced that Altera Corporation licensed its MIPS32(R) architecture, marking the entry of the MIPS(R) architecture into the FPGA channel.
continued... |
|
| Sep 30, 2009 | 10:00 | Cytomedix Enters License Agreement With Millennia Holdings for Exclusive Rights to the AutoloGel System in Japan |
| Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announces that the Company has entered into a license and distribution agreement with Millennia Holdings, Inc. ("Millennia") for the Company's AutoloGel(TM) System in Japan. The AutoloGel(TM) System is the Company's proprietary, point-of-care device for the production of Platelet Rich Plasma ("PRP") gel derived from the patient's own blood and is indicated for use in exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds. The agreement provides territorial exclusivity for 10 years with the option to extend terms upon agreement by both parties.
continued... |
|
| Sep 24, 2009 | 08:30 | Skinvisible Signs License Agreement for DermSafe to Fight H1N1 |
| Skinvisible, Inc. (OTCBB:SKVI), a pharmaceutical research and development company, announced today that it has entered into an exclusive license agreement with Mayquest Pharmaceuticals Pte. Ltd. for the rights for DermSafe(R), Skinvisible's patented antimicrobial hand sanitizer lotion proven to kill the H1N1 swine flu virus. The license agreement includes Singapore, Malaysia, Thailand, Indonesia and the Philippines.
continued... |
|
| Sep 21, 2009 | 08:15 | Icagen Announces Extension of Pfizer Collaboration |
 | Icagen, Inc. (Nasdaq:ICGN) today announced a one year extension to a prior worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders.
continued... |
|
| More >>
|
